Lupus anticoagulant testing-sometimes mixing is required: Potential for false negatives without mixing studies

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 6, 2013, Pages 673-676

  Favaloro, Emmanuel J ^a   Bonar, Roslyn ^b   Marsden, Katherine ^c  

^a WESTMEAD HOSPITAL   (Australia)

^b RCPAQAP Haematology   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ECARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; REAGENT; SNAKE VENOM;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TIME; DILUTE RUSSELL VIPER VENOM TIME; FALSE NEGATIVE RESULT; HUMAN; LABORATORY TEST; LETTER; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUALITY CONTROL; SILICA CLOTTING TIME; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; THROMBOSIS;

EID: 84882412157     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328360c71b     Document Type: Letter

References (21)

1. Favaloro EJ, Wong RCW. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours Autoimmunity Highlights 2010; 1:5-14.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
3. Favaloro EJ, Wong R. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49:447-461.
4. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38:375-384.
5. Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems. Blood Coagul Fibrinolysis 2012; 23:739-744.
6. Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. J Thromb Haemost 2003; 1:2689-2691.
7. Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thromb Res 2006; 118:523-528.
8. Aboud M, Roddie C, Ward C, Coyle L. To mix with pooled plasma or not to mix; a comparative study of two approaches to assess lupus anticoagulant inhibitory activity in the dilute Russell viper venom method. Clin Chem 2007; 53:143-145.
9. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II-lupus anticoagulant. Semin Thromb Hemost 2012; 38:404-411.
10. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737-1740.
11. Tripodi A, Pengo V. More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2011; 9:2126-2127.
12. Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8:2828-2831.
13. Tripodi A. To mix or not to mix in lupus anticoagulant testing That is the question. Semin Thromb Hemost 2012; 38:385-389.
14. Bonar R, Favaloro EJ, Zebeljan D, Rosenfeld D, Kershaw G, Mohammed S, et al. Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP. Pathology 2012; 44:240-247.
15. Favaloro EJ. Trials and tribulations in lupus anticoagulant testing. Clin Chem Lab Med 2013; 51:253-256.
16. McGlasson DL, Fritsma G. Comparison of six dilute Russell Viper Venom Time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 2013; 39:315-319.
17. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827-1832.
18. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010; 19:440-445.
19. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 2012; 38:339-347.
20. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157:47-58.
21. Stief TW. ß2-Glycoprotein-1 antibodies trigger thrombin generation. Hemostasis Lab 2009; 2:223-246.